APGEApogee Therapeutics

Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG...

(RTTNews) - Apogee Therapeutics, Inc. (APGE) on Wednesday announced a financing partnership with Blackstone Life Sciences that could provide up to $1.3 billion in non-dilutive capital to help advance and potentially commercialize its lead drug candidate, zumilokibart...

Apogee Therapeutics (NASDAQ:APGE) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-apogee-therapeutics-inc-stock...

Rothschild & Co Redburn upgraded Apogee Therapeutics to a "strong-buy" rating in a research report on Friday...

Jennison Associates LLC purchased a new position in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 578,627 shares of the company's stock, val...

Pictet Asset Management Holding SA bought a new stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to its most recent filing with the Securities...

Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High - Time to Buy...

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seventeen brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recomme...

Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $82.58, for a total transaction of $1,651,600.00. Following the completion of the...